Brain-Targeted Drug Delivery

• Autore: Sousa Flávia
• Pubblicazione: MDPI - Multidisciplinary Digital Publishing Institute, 2022
• Descrizione fisica: 1 online resource (260 p.)
• Soggetto topico: Technology: general issues
• Soggetto non controllato: 3D cell culture systems; acetaminophen; Alzheimer's disease; Alzheimer's disease-relevant tau species; anti-tau and anti-receptor bispecific monoclonal antibodies; blood-brain barrier; brain biodistribution; brain cancer; brain targeted therapy; central composite rotatable design; cerebral open flow microperfusion; cerebrospinal fluid microcirculation; chemoattractant; claudin-5; CNS drug delivery; convection-enhanced delivery; CXCL; CXCR; delivery to brain; depression; diffuse midline glioma; drug delivery; drug delivery into the brain; electrochemical biosensors; GB-13; gene therapy; glioblastoma; glioblastoma multiforme; glycol chitosan; high-grade glioma; hyaluronidase; IL-13; IL-13Rα2; IL13.E13K-PE4E; immunotherapy; immunotoxin; improved memory; interactions between Aβ and tau; intranasal delivery; laser; liposome; macromolecules; memory impairment; microdialysis; microparticles; movement impairment; n/a; nanoparticle; nanoparticles; nanostructured lipid carrier; naringenin; nasal delivery system; neurosurgery; non-human primate; nose to brain delivery; opioids; optogenetics; Parkinson's disease; phospholipid oily gel; PLGA; polyplexes; pomegranate seed oil; receptor expression; seizure; targeted therapy; tau clearance in microglia; tau clearance in neurons; temporal-spatial pathological Aβ and tau distribution; tight junction; tolcapone; transendothelium based on receptor-mediated transcytosis; ultrasound
• Persona (resp. second.): SousaFlávia
• Sommario/riassunto: Brain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer's and Parkinson's diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood-brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems.
• Titolo autorizzato: Brain-Targeted Drug Delivery
• ISBN: 3-0365-5281-2
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Lingua di pubblicazione: Inglese
• Record Nr.: 9910619467203321
• Lo trovi qui: Univ. Federico II